Institut Pasteur and University of the West Indies, Mona Join Renowned Global Virus Network to Combat Viral Diseases

Institut Pasteur and University of the West Indies, Mona Join Renowned Global Virus Network to Combat Viral Diseases

Baltimore, Maryland, USA, May 24, 2016: The Global Virus Network (GVN), representing 36 Centers of Excellence and 6 Affiliates in 24 countries comprising foremost experts in every class of virus causing disease in humans, announced today the addition of the Institut Pasteur as its newest Center of Excellence and the University of the West Indies, Mona (UWI) as its newest Affiliate Center of Excellence. The announcement was made by Robert Gallo, MD, GVN Co-Founder and International Scientific Advisor and José Esparza, MD, PhD, GVN President.

“These two new additions are particularly important as they strengthen GVN’s international reach,” said Dr. Gallo, who is also Director of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine, a GVN Center of Excellence. “I have a long history of working with Institut Pasteur and look forward to collaborating again through GVN initiatives. Their science is superb and their network impressive.” Dr. Gallo continued, “We also look forward to working with colleagues in Jamaica through UWI to explore new research projects, such as those involving endemic viruses in the region including HIV and HTLV, and to examine and implement best practices as we work together to enhance the global safety net against viral disease.”

“GVN has an important role to play in our preparedness and response to emerging viral threats, especially in the aspects related to research and development,” said José Esparza, MD, PhD, GVN President. “Institut Pasteur and UWI strengthen our ability to facilitate collaborations and solve complex viral problems.”

The Institut Pasteur in Paris, France is an internationally renowned center for biomedical research with a network of 33 institutes worldwide. In the pursuit of its mission to prevent and fight against diseases in France and throughout the world, the Institut Pasteur operates in four main areas: scientific and medical research, public health and health monitoring, teaching, and business development and technology transfer. Institut Pasteur’s GVN co-directors include Antoine Gessain MD, PhD, Professor, Chief of the Oncogenic Virus Epidemiology and Pathophysiology, and Marc Lecuit MD, PhD, Head of the Biology of Infection Unit.

The University of the West Indies (UWI), Mona was inducted into the GVN as an affiliate through collaborations with three GVN Centers of Excellence including the Institute of Human Virology (IHV) at the University of Maryland School of Medicine; University at Buffalo (UB), State University of New York; and, Colorado State University (CSU). The UWI/Jamaica—GVN collaboration, led by John Lindo, BSc, PhD, professor and associate dean in the Faculty of Medical Sciences and department chair for microbiology at UWI, will build local capacity in the prevention and management of diseases caused by viruses by increasing research and training opportunities through GVN and partner organizations.

“UWI Mona has Jamaica’s only virus laboratory with the capability of handling live viruses for medical diagnosis and scientific research,” said Dr. Lindo. “It also has a cadre of highly trained virologists and is the site of the National Influenza Center. Using this unique capability in the country, UWI will collaborate with GVN, leveraging their expertise, to better respond to outbreak of viruses such as dengue, chikungunya and Zika in Jamaica and better prepare for additional global threats including Influenza and Ebola.”

Scott Weaver with First Robert C. Gallo Award

Global Virus Network (GVN) Presents Mosquito-Borne Virus Expert for Scientific Excellence
The Award was presented during a meeting organized by Emory University and co-sponsored by the GVN on the Zika virus
May 2, 2016, Atlanta, GA: The Global Virus Network (GVN), representing 35 Centers of Excellence and 5 Affiliates in 26 countries, and comprising foremost experts in every class of virus causing disease in humans, today announced Scott Weaver, MS, PhD, as the first recipient of the GVN Robert C. Gallo Award for Scientific Excellence. Dr. Weaver is Chair of GVN’s Chikungunya and Zika Task Forces as well as director of the University of Texas Medical Branch’s Institute for Human Infections and Immunity and scientific director of the Galveston National Laboratory, a GVN Center of Excellence. The Award was presented by José Esparza, MD, PhD, president of the GVN and Raymond Schinazi, PhD, Hon Dsc, member of the GVN Board of Advisors and Zika Task Force and the Frances Winship Walters Professor at Emory University. The honor was bestowed during a scientific meeting entitled, “Bridging the Sciences: Zika Virus,” organized by Emory University and co-sponsored by GVN in Atlanta, Georgia May 1-3, 2016.

L to R: Raymond Schinazi, PhD, Hon Dsc, Emory University; Scott Weaver, MS, PhD, Galveston National Laboratory; José Esparza, MD, PhD, president of the GVN; Mario Stevenson, PhD, University of Miami Miller School of Medicine; and, Suzane K Ono-Nita, MD, PhD, University of São Paulo

“It was unanimous when deciding who should receive the inaugural Award, and it is my great pleasure that Dr. Scott Weaver will be the first honoree,” said Dr. Robert C. Gallo, Co-founder and International Scientific Advisor of the Global Virus Network (GVN), The Homer and Martha Gudelsky Distinguished Professor in Medicine, co-founder and director of the Institute of Human Virology at the University of Maryland School of Medicine, a GVN Center of Excellence. “Dr. Weaver is not only a leader in the GVN, but an exceptional public health virologist who is most deserving of this recognition. A warm congratulations to Dr. Weaver.”

 

[one_whole]Scott Weaver, MS, PhD Biography

Scott Weaver, MS, PhD, is a virologist and vector biologist who advances our understanding of arthropod-borne viruses (arboviruses) and their transmission by mosquitoes, and develops vaccines to control the diseases that they cause. As a faculty member since 1994 at the University of Texas Medical Branch (UTMB) in Galveston, he has developed an internationally recognized research program encompassing the ecology and epidemiology of enzootic arbovirus transmission cycles, virus-mosquito interactions, and emergence mechanisms of epidemic strains. Dr Weaver utilizes his broad training to develop interdisciplinary approaches that have had major impacts on our understanding of arboviral disease emergence. These include Venezuelan equine encephalitis, for which the international research groups he has led determined the ecological and evolutionary sources as well as mechanisms of epidemic strain emergence. Dr Weaver’s recent studies have focused on chikungunya virus, its history of emergence from wildlife African cycles, mosquito-adaptive evolution, and its viral genetic constraints, as well as Zika virus, which arrived in the Americas and is causing a major epidemic associated with congenital microcephaly and Guillain Barré syndrome. His research on tropical arboviral diseases has included major field studies in Venezuela, Colombia, Peru, Mexico, Panama, Senegal, and Kenya. Dr Weaver has also developed promising new vaccines for several of these arboviral diseases. The chikungunya vaccine developed in his laboratory, licensed to Takeda Pharmaceuticals and patented in 19 countries, is in late preclinical evaluation.

Dr Weaver’s research has led to over 260 peer-reviewed publications in scientific journals, and over 70 reviews and book chapters. He has mentored 18 PhD students as well as 23 postdoctoral fellows, and many have gone on into prominent, independent scientific positions in government, academia, and industry. Dr Weaver’s research and educational contributions have been recognized with many local and international awards. In 2014 he received the Walter Reed medal, awarded every three years by the American Society of Tropical Medicine and Hygiene for distinguished career accomplishments in tropical medicine research. His many leadership positions include his current role as chair of the Global Virus Network’s Chikungunya and Zika Task Forces. He also serves as an editor for several major tropical medicine and microbiology journals. At UTMB, Dr Weaver leads the Institute for Human Infections and Immunity (IHII), which coordinates infectious disease research as the administrative home of the Galveston National Laboratory (one of two NIH-funded national biocontainment facilities); the Sealy Center for Vaccine Development; the Center for Biodefense and Emerging Infectious Diseases; and the Center for Tropical Diseases. He is also scientific director of the Galveston National Laboratory, and interim chair of the Department of Microbiology and Immunology.

[/one_whole]